A hormone could help limit scarring and damage in the liver.
Rates of nonalcoholic steatohepatitis are rising worldwide. The condition is a complication of nonalcoholic fatty liver disease, where – as well as there being fat in the liver – there is also inflammation and damage. There are no effective treatments, especially once fibrosis or scar tissue develops. Now, a Japanese study has uncovered a mechanism through which a hormone called IGF-I may limit such damage.
Nonalcoholic fatty liver disease (NAFLD) is a condition where, like alcoholic liver disease, fat builds up in the liver – except it is also found in people who drink little or no alcohol.
Scientists are not sure what causes NAFLD, although obesity is a clear risk factor. Other risk factors include diabetes, high cholesterol, high blood pressure, high blood fats, advancing age, and smoking.
|Read Full Article: Nonalcoholic fatty liver disease: Hormone that limits fibrosis discovered – Medical News Today|